Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

Cord Blood America Contracts With Center for Stem Cell Awareness to Sell Collection and Storage Services in Florida

LAS VEGAS, Jan. 19 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has contracted with The Center for Stem Cell Awareness to re-sell its stem cell collection and storage services.

The Center for Stem Cell Awareness, Inc., Sarasota, Florida (http://www.babyslifeline.com/) has contracted to sell these services throughout the state of Florida.

"This is another very important step forward for Cord Blood America. As a direct result of processing and storing cord blood stem cells in our own laboratory, it allows CBAI to contract partners who will sell our services without CBAI's out-of-pocket investment to develop a new territory. We are fortunate to work with The Center for Stem Cell Awareness, and are very pleased to make this announcement," said Matthew Schissler, CBAI co-founder and CEO.

The Center for Stem Cell Awareness, founded by Joan and Jeff Williams, was a personal endeavor based on a real life scenario with their daughter. Realizing that most expectant parents have no idea about the research and medical breakthroughs with cord blood stem cells, they started their company with the goal of providing an educational resource for expectant families and their physicians to draw upon.

About The Center for Stem Cell Awareness, Inc. Center for Stem Cell Awareness Story:

Ten years ago we decided to save our daughter's cord blood stem cells. Our physicians at that time were aware of this procedure but freely admitted that they had never done this before, not even for one of their patients. At this time, my husband's older sister had just been diagnosed with Leukemia. According to the information we received, Leukemia was a disease that could be treated with using stem cells. We felt that the important power of our daughter's stem cells might offer her protection from this disease and others. One year ago our daughter was diagnosed with juvenile diabetes. Juvenile diabetes is also known as type 1 or insulin dependent diabetes. I am thankful everyday that we saved her stem cells from her cord blood.

When she was diagnosed with diabetes all of her physicians stated that it was probably a wise decision to have saved her cord blood cells, but they did not think anything was being done in conjunction with cord blood stem cells and diabetes. Upon further research we discovered that there are studies underway to determine the best way to use her cord cells to hopefully reverse this disease. We want every expectant parent to know the facts about the importance of cord blood and all the medical advancements in this field. We wanted to allow interested parties to have someone locally to discuss the importance of this decision and answer all of their questions, and to hopefully provide guidance in this decision making process. Most importantly, to allow you to participate in this process at the best pricing possible.

Contact: Joan Williams http://www.babyslifeline.com/ 941-806-8693 ____________________ About Cord Blood America

Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com

Cord Blood America, Inc.

CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.; or Joan
Williams, +1-941-806-8693, for The Center for Stem Cell Awareness, Inc.

Web Site: http://www.cordblood-america.com/

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.